An examination of GIPR-specific Gs-cAMP-PKA/EPAC2 signaling in pancreatic beta cells and adipocytes, exploring differential receptor expression patterns versus GLP-1R in rodent metabolic models.

A preclinical review of GLP-1 receptor agonist effects on AMPK activation, mTOR suppression, and autophagic flux restoration in rodent myocardial ischemia-reperfusion models.

A research-context examination of glucagon receptor agonism and hepatic glucose regulation: what retatrutide’s triple-receptor profile reveals about liver signaling, analyzing preclinical molecular evidence and known translational limitations.

This article examines the GIP receptor signaling architecture in white adipose tissue depots, exploring cAMP-PKA-HSL cascade modulation and nonadipocyte cellular contributions in preclinical research models.

A research-context examination of retatrutide triple receptor agonism effects on osteoblast signaling pathways, RANKL/OPG modulation, and the translational gaps in skeletal biology models.

A research-context examination of retatrutide’s GIPR arm, focusing on Gs-coupled cAMP/PKA signaling, adiponectin pathway modulation, and MAPK/ERK cross-signaling in preclinical adipose tissue models.

Preclinical evaluation of Retatrutide’s selective glucagon receptor (GCGR) activation and hepatocyte mitochondrial beta-oxidation signaling cascades.

Preclinical characterization of triple agonist LY3437943 signaling kinetics, Gs-protein pathways, and Rab-mediated receptor endocytosis dynamics.

A research-context analysis of retatrutide’s GIPR-specific cAMP-PKA signaling mechanism and how it differs from GLP-1R and glucagon receptor activation in preclinical metabolic models.

This article examines Retatrutide’s Glucagon Receptor activation mechanisms and downstream mitochondrial dynamics in preclinical models.